Increased mean platelet volume (MPV) is associated with platelet reactivity and is a predictor of cardiovascular risk and unprovoked nervous thromboembolism. Mean platelet volume is a precise measure of platelet size. Studies have reported the use of MPV as a biomarker for predicting ischemic stroke in atrial fibrillation patients as well as in anticoagulant prescription and rhythm-control therapy. Moreover, MPV may predict cardiovascular event outcome following percutaneous coronary intervention in patients with coronary artery disease. MPV may predict residual platelet reactivity in dual antiplatelet therapy. Factors influencing MPV result were discussed. This review centered on the reports that MPV may be a biomarker of risk and prognosis of prevalent heart diseases.
Mean platelet volume; cardiovascular disease; atrial fibrillation; myocardial infarction; biomarker.